15 results about "Interleukin 5" patented technology

The present invention relates to pharmaceutical formulations of antibodies and antigen-binding fragments against Interleukin 5 (IL-5) comprising buffer and one or more amino acids. The disclosed formulations are stable IL-5 antibodies formulations suitable for parenteral route of administration.

The invention provides a human interleukin 5 alpha receptor IL5RA mRNA (messenger Ribonucleic Acid) detection primer probe group, a kit and application, and belongs to the technical field of biological detection. A detection primer probe group is limited to comprise IL5RA-F, IL5RA-R and a probe I5-Probe, the expression level of human interleukin 5 alpha receptor (IL5RA) mRNA is detected in cooperation with an RNA one-step method, the content change of IL5RA can be sensitively detected, and compared with an immunological detection method, the detection sensitivity can be greatly improved, a low-concentration clinical sample can be detected, and the detection method has the advantages that the detection time is shortened, and the detection cost is reduced. The detection range can span at least five orders of magnitude, the accuracy of the detection result is improved, and at least 80 persons can be detected within one hour, so that the treatment effect can be dynamically monitored and evaluated more accurately and quickly in an earlier stage.

The present disclosure relates to pharmaceutical compositions comprising from about 100 mg to about 300 mg of an antigen binding protein which binds to IL-5. Compositions and antigen binding proteins of the disclosure are useful in the treatment of IL-5 mediated diseases, such as EGPA, HES, CRSsNP and CRSwNP, and can be administered about once every 6 months.

The invention provides a method of diagnosing overactive bladder disorder (OAB), the method comprising: measuring the concentrations of one or more of adenosine triphosphate (ATP), acetylcholine (ACh), nitric oxide (NO) and interleukin 5 (IL-5) in a sample obtained from a subject; normalising the concentrations to the concentration of creatinine (Cr) in the sample; range standardising the normalised concentrations and subject's age to the following values: Age to 120 years old; ATP / Cr to 0.000001; ACh / Cr to 0.1; NO to 20000; IL-5 / Cr to 100; wherein the likelihood of having OAB (pOAB)=1 / 1+e−x, where X=one or more of the following: (a) (−2.688±1.050)+5.472±2.098×subject's age+1.356±0.559×Gender (Female=1, Male=0)+(−7.998±40.273)×[IL-5 / Cr]; (b) (−2.141±0.966)+4.506±1.902×subject's age+1.034±0.519×Gender (Female=1, Male=0)+(−5294.063±9075.456)×[ACh / Cr]; (c) (−2.825±1.072)+5.964±2.167×subject's age+1.312±0.562×Gender (Female=1, Male=0)+17.790±58.762×[IL-5 / Cr]+(−9180.821±12700.057)×[ACh / Cr]; (d) (−2.993±1.197)+5.580±2.309×subject's age+1.724±0.719×Gender (Female=1, Male=0)+63.571±73.444×[IL-5 / Cr]+(−0908.523±13606.752)×[ACh / Cr]+(−566.991±636.589)×[ATP / Cr]; (e) (−3.090±1.200)+5.393±2.256×subject's age+1.797±0.717×Gender (Female=1, Male=0)+34.767±56.331×[IL-5 / Cr]+(−562.743±629.316)×[ATP / Cr]; or (f) (−2.650±1.067)+5.516±2.120×subject's age+1.389±0.583×Gender (Female=1, Male=0)+(−4.060±45.238)×[IL-5 / Cr]+(−1.456±6.833)×[NO / Cr]; and wherein a pOAB above a threshold indicates that the subject has a high likelihood of having or developing OAB and a pOAB below a threshold indicates that the subject does not have OAB.

The present disclosure relates to compositions, for treating interleukin 5 (IL-5) mediated diseases, and related methods.

The present invention relates to a method of diagnosing over active bladder disorder (OAB), the method comprising: measuring the concentrations of adenosine triphosphate (ATP), acetylcholine (ACh), nitrite, monocyte chemoattractant protein 1 (MCP-1) and interleukin 5 (IL-5) in a sample obtained from a subject; normalising the concentrations to the concentration of creatinine (Cr) in the sample; range standardising the normalised concentrations and subject's age to the following values: Age to 120 years old; ATP / Cr to 0.000001 mole / mg×dl−1; ACh / Cr to 0.1 mole / mg×dl−1; Nitrite to 200 nM / mg×dl−1; MCP-1 / Cr to 100 pg×ml−1 / mg×dl−1; IL-5 / Cr 100 pg×ml-mg×dl−1; applying the normalised and range standardised concentrations to the following formula: Logit (p)=−1.738±1.404±4.985±2.914×subject's age+3315.959±5435.254×[ATP] / [Cr]+(−25204.194±20268.337)×[ACh] / [Cr]+26.799±32.967×[nitrite] / [Cr]+6.755±25.132 [MCP-1] / [Cr]+(−61.838±148.740) [IL-5] / [Cr] and calculating Logit; wherein a Logit value above a predetermined threshold indicates that the subject has OAB. Methods for monitoring the progression of OAB using the method, kits for use in the method and computer systems and programs configured to execute the method are also provided.

The present disclosure relates to compositions for treating interleukin 5 (IL-5) mediated diseases, and related methods.

The present disclosure relates to compositions, for treating interleukin 5 (IL-5) mediated diseases, and related methods.

The present disclosure relates to antigen binding compositions, including antibodies, and related methods for treating interleukin 5 (IL-5) mediated diseases. IL-5 is a secreted protein. IL-5 plays a role in a variety of different diseases, such as asthma, mild asthma, moderate asthma, severe asthma, mild eosinophilic asthma, moderate eosinophilic asthma, severe eosinophilic asthma, uncontrolled eosinophilic asthma, eosinophilic asthma, sub-eosinophilic asthma, chronic obstructive pulmonary disease, eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome, nasal polyposis, bullous pemphigoid, eosinophilic esophagitis, atopic dermatitis, moderate atopic dermatitis, and severe atopic dermatitis. The disclosed compositions are suitable for treating these severe IL-5 mediated diseases.

The present application relates to multispecific binding agents that bind to both interleukin-4 receptor alpha (IL-4Rα) and interleukin 5 (IL-5). The present application further provides compositions (e.g., pharmaceutical compositions) comprising the multispecific binding agents provided herein and uses thereof.

The present disclosure relates to compositions for treating interleukin 5 (IL-5) mediated diseases, and related methods.

The present disclosure relates to compositions for treating interleukin 5 (IL-5) mediated diseases, and related methods.

The present disclosure relates to compositions for treating interleukin 5 (IL-5) mediated diseases, and related methods.

The present disclosure relates to compositions, for treating interleukin 5 (IL-5) mediated diseases in pediatric subjects, and related methods.

The present disclosure relates to compositions and related methods for treating interleukin 5 (IL-5) mediated diseases in a pediatric subject.